Objectives: To evaluate the long-term functional outcomes of robot-assisted partial nephrectomy (RAPN) in patients with and without a solitary kidney.
Materials And Methods: A retrospective review was performed using the prospectively maintained, institutional review board-approved database to identify all consecutive patients who underwent RAPN between 2006 and 2023. A propensity-score-matched analysis was subsequently undertaken to compare patients with and without a solitary kidney.
Objective: To develop a predictive tool to assist in predicting the risk of Acute Kidney Injury (AKI) following robot-assisted partial nephrectomy (RAPN).
Methods: A retrospective review was performed on the prospectively maintained, IRB-approved database to identify all consecutive patients who underwent RAPN between 2008 and 2023. Patients with end-stage kidney disease (ESKD), horseshoe kidneys, solitary kidneys, and previous renal transplant recipients were excluded.
Objective: Our study presents a novel analysis of the oncogenes and tumor suppressor proteins directly modulated by E6/E7 of high-risk HPV types 16 and 18, in colorectal cancer (CRC).
Methods: HCT 116 (KRAS mutant) & HT-29 (TP53 mutant) cell models of CRC were transduced with E6/E7 of HPV16 and HPV18, individually and in combination. Further, we utilized a liquid chromatography mass spectrometry (LC-MS/MS) approach to analyze and compare the proteomes of both CRC cell models.
In this research, S-scheme heterojunction photocatalysts are prepared through the hybridization of nitrogen-rich g-CN with TiO (coded as TCN-(): as the weight ratio of TiO:g-CN). The photocatalytic potential of TCN-() is evaluated against benzene (1-5 ppm) across varying humidity levels using a dynamic flow packed-bed photocatalytic reactor. Among the prepared composites, TCN-(10) exhibits the highest synergy between g-CN and TiO at "" ratio of 10%, showing superior best benzene degradation performance (e.
View Article and Find Full Text PDFDiabetic macular edema (DMO) poses a significant risk to vision, primarily caused by the leakage of retinal vessels. Traditional treatments involve anti-vascular endothelial growth factor (VEGF) agents and corticosteroids, though responses vary, necessitating frequent treatments. This retrospective study at a London-based tertiary eye hospital evaluates the efficacy of faricimab, a bispecific antibody inhibiting angiopoietin 2 (Ang-2) and VEGF-A, in treating DMO.
View Article and Find Full Text PDF